Skip to main content
N4 PHARMA PLC logo

N4 PHARMA PLC — Investor Relations & Filings

Ticker · N4P ISIN · GB00BYW8QM32 LEI · 213800I841D2RKMFK955 IL Professional, scientific and technical activities
Open in API
Filings indexed 840 across all filing types
Latest filing 2017-08-08 Earnings Release
Country GB United Kingdom
Listing IL N4P

About N4 PHARMA PLC

https://n4pharma.com/

N4 Pharma PLC is a specialist pharmaceutical company focused on the development of Nuvec®, its proprietary silica nanoparticle delivery system. This platform technology is designed to enhance the cellular delivery and potency of nucleic acid-based treatments, such as vaccines and cancer therapies. The company's primary focus is on applying Nuvec® to enable advanced therapies for oncology and infectious diseases. N4 Pharma's business model involves developing and out-licensing its technology to pharmaceutical and biotechnology partners to improve the performance of new and existing drugs.

Recent filings

Filing Released Lang Actions
Verona Pharma plc Interim Results for the Six Months Ended June 30, 2017 and Clinical Development Update
Earnings Release Classification · 1% confidence The document is an announcement from Verona Pharma regarding its interim financial results for the six months ended June 30, 2017. It includes key financial highlights (operating loss, loss after tax, net cash) and clinical development updates. While it contains financial data, it is structured as a press release announcing the results rather than the full, formal interim report document itself. According to the classification rules, this fits the definition of an Earnings Release (ER) as it provides the initial announcement of periodical financial results and key highlights. H1 2017
2017-08-08 English
Verona Pharma to Announce Interim Results for Six Months Ended June 30, 2017 and Provide Clinical Development Update
Report Publication Announcement Classification · 1% confidence The document explicitly states that Verona Pharma plc "announces today that it will report its interim results for the six months ended June 30, 2017 on Tuesday, August 8, 2017." It then details the conference call schedule to discuss these results. This is an announcement about the upcoming release of periodic financial results (interim results) and the associated call, rather than the full report itself (which would be an IR or ER). Since it is announcing the release of interim financial results and scheduling a call, it strongly aligns with the function of an Earnings Release (ER) or a precursor announcement. However, given the specific mention of 'interim results' and the short length (3382 chars) combined with the announcement of the release date and call details, it functions as a notification about the upcoming financial disclosure. The closest fit among the options is 'Earnings Release' (ER) for announcing periodical results, or potentially 'Report Publication Announcement' (RPA) because it announces the publication date. Since the core content is the announcement of the *interim results* discussion, ER is a strong candidate, but RPA is often used for announcements *about* reports. Given the context of announcing the *interim results* and the call, ER is slightly more specific to the financial event being announced than a generic RPA. However, if we strictly follow the 'MENU VS MEAL' rule, this is an announcement *about* the results, not the results themselves. Since there isn't a specific code for 'Earnings Call Announcement', and it's announcing the release of financial results, I will classify it as an Earnings Release (ER) as it pertains to the core financial reporting event, or RPA if strictly adhering to the announcement nature. Given the focus on the *interim results* date, ER is the most relevant financial category. If the document was purely about the *timing* of a previously announced report, RPA would be better. Here, the announcement *is* the key news item regarding the results. I will lean towards ER as the most specific financial event being announced.
2017-08-02 English
SFX-01 data published in Peer Reviewed Journal
Regulatory Filings Classification · 1% confidence The document begins with an 'RNS Number' and is dated '02 August 2017'. The content announces the publication of scientific data for a product (SFX-01) in a peer-reviewed journal. The structure, use of RNS numbering, and the nature of the announcement (a general update on scientific progress/publication) strongly suggest this is a regulatory news service announcement. Since it is not a full financial report (10-K, IR), a specific management change (MANG), or a dividend notice (DIV), and it is clearly a general regulatory disclosure distributed via RNS, the most appropriate classification is Regulatory Filings (RNS). The document length is short (3724 chars), fitting the profile of a brief announcement rather than a comprehensive report.
2017-08-02 English
Result of AGM
AGM Information Classification · 1% confidence The document explicitly states it is an RNS (Regulatory News Service) announcement with the RNS Number 2238M. The title is 'Result of AGM', and the body confirms that 'all resolutions were duly passed at its Annual General Meeting ("AGM") held yesterday afternoon.' This directly relates to the outcome of a shareholder vote following an AGM. The most specific category for official results from shareholder votes is 'Declaration of Voting Results & Voting Rights Announcements' (DVA). Although it mentions the AGM, the core content is the result confirmation, not the AGM presentation materials (AGM-R) or the proxy solicitation materials (PSI).
2017-07-27 English
Update on Sildenafil clinical plans
Legal Proceedings Report Classification · 1% confidence The document is identified by the 'RNS Number' header and the concluding statement 'This information is provided by RNS The company news service from the London Stock Exchange'. This indicates it is a regulatory announcement disseminated through the London Stock Exchange's Regulatory News Service (RNS). The content discusses an update on clinical trial plans, specifically the appointment of a contractor for a pilot trial for Sildenafil reformulations. This type of operational or clinical update, when disseminated via RNS and not fitting into more specific categories like Director's Dealing (DIRS), Earnings Release (ER), or Capital Change (SHA), falls best under the general 'Regulatory Filings' category, which serves as the fallback for miscellaneous regulatory announcements. Given the document length (4573 chars) and content, it is a substantive announcement, not just a notice of publication (RPA). Therefore, RNS is the most appropriate classification.
2017-07-27 English
Charity-funded Study of SFX-01 in TNBC
Regulatory Filings Classification · 1% confidence The document is identified by the header 'RNS Number : 7315K' and concludes with 'This information is provided by RNS The company news service from the London Stock Exchange END'. RNS stands for Regulatory News Service, which is a general regulatory announcement mechanism, often used for immediate, material news that doesn't fit a more specific SEC filing category (like 10-K or DEF 14A). The content is an announcement about a new preclinical study involving the company's product, which is material news. Since it is explicitly labeled as an RNS release and serves as a general regulatory announcement, the most appropriate classification is RNS.
2017-07-11 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.